Earlier this week, Axsome (NASDAQ: AXSM ) published topline data from the open-label, follow on phase 3 study of AXS-12 (reboxetine) for the treatment of narcolepsy patients with cataplexy. The trial met its primary endpoint of change in frequency of weekly cataplexy attacks fromAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticke ...